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Abstract
Introduction. Our knowledge in the field of cause of deaths in dialysis patients is rapidly expanding, yet we still do not 
fully understand how renalase regulates the processes of cardiovascular disease developing in end-stage renal disease. 
Increased sympathetic nerve activity observed in chronic kidney diseases due to raised catecholamines in plasma results 
from the absence of renalase. Renalase synthesized and secreted by the kidneys participate in the regulation of sympathetic 
tone and blood pressure. A family of natriuretic peptides has been identified – NT pro-BNP – which seems to be the best 
predictor of clinical outcome and marker of extracellular fluid overload, as well as predicting mortality, irrespective of renal 
function.   
Objective. The aim of the presented study was to investigate renalase concentration and investigate associations between 
NT-proBNP, as well as analyzed parameters in haemodialysis patients.   
Materials and method. The study was conducted among residents of the municipality and neighbouring villages in 
the province of Lublin, central-eastern Poland. 49 male subjects on haemodialysis, aged 65.3 ± 14.2 years, median time 
on haemodialysis: 37.5 months, were included. All study subjects underwent haemodialysis 3 times a week. The mean 
concentration of renalase in the entire study population was 126.59 ± 32.63 ng/mL. The circulating levels of NT-proBNP 
was 813.64 ± 706.96 pg/mL. A significant inverse correlation was found between NT-proBNP and renalase plasma levels 
(R = –0.3, P = 0.03).   
Conclusions. Inverse correlation between NT-proBNP and renalase plasma levels in haemodialysis patients were due to 
impaired kidney function, accompanied by increased sympathetic nerve activity, which have an impact on the development 
of hypertension and cardiovascular complications.
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INTRODUCTION
Our knowledge in the field of the cause of deaths in dialysis 
patients are rapidly expanding, yet we still do not fully 
understand the problem of high mortality in patients on 
dialysis. The major cause of death in haemodialysis (HD) 
patients is cardiovascular disease (CVD), which constitute 
53% of causes of death in Poland [1]. In addition to traditional 
risk factors for CVD, such as hypertension – diabetes and lipid 
disorders are also responsible. Other determinants are, e.g. 
anaemia, volume overload of the circulatory system associated 
not only with renal failure (RF), but also the presence of 
arteriovenous anastomosis and rapid changes in blood volume 
during HD, chronic systemic inflammation, accumulation 
of uraemic toxins and disorders of calcium and phosphate. 
Most patients starting dialysis are hypertensive, suggesting 
that blood pressure (BP) control is an important target for 
reducing cardiovascular mortality [2]. Catecholamines (CA) 
are able to regulate many biological processes and are closely 
related to regulating blood pressure. Increased sympathetic 
nerve activity observed in chronic kidney diseases, is due 
to raised CA in plasma resulting from inhibition of nitric 
oxide, followed by increased angiotensin II and the absence 
of renalase, as well as reduced CA clearance in the kidneys. 
Moreover, raised sympathetic activity is now recognized 
as an important mechanism involved in cardiovascular 
complication in humans [3]. Importantly, CVD disease 
is a major complication in patients with chronic kidney 
disease (CKD) and has a main impact on morbidity and life 
expectancy of adults. Myocardial disease in CKD patients, 
as part of the more generalized cardiovascular disorder, is 
manifested as left ventricular hypertrophy (LVH), diastolic 
dysfunction and, to a lesser extent, systolic dysfunction [4].
There are multiple factors involved in the control of BP 
and CVD developing in ESRD. Renalase is a protein made 
of 342 amino acids. Recently discovered as a new renal 
hormone, renalase – flavin adenine dinucleotide (FAD)-
dependent amine oxidase [5], is secreted by the kidneys 
and metabolizes circulating CA [6], as well as perhaps 
playing a role in the regulation of sympathetic tone and 
blood pressure. It has a significant haemodynamic effect; 
therefore, it is likely to participate in the regulation of 
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cardiovascular function, although its exact mechanism 
remains unclear. Current studies indicate that the plasma 
renalase levels are decreased in patients with CKD and ESRD. 
This is particularly significant as the abnormal regulation of 
catecholamine metabolism contributes to the pathogenesis 
of LVH, ventricular arrhythmia, myocardial ischemia (MI) 
and myocardial necrosis [7]. Growing evidence suggests 
that renalase may contribute to the development of cardiac 
dysfunction.
B-type natriuretic peptides (BNP) belong to the natriuretic 
peptide family, which is comprised of 4 peptide hormones. 
BNP is secreted predominantly by cardiomyocytes from 
the left ventricle. The hormone BNP is cleaved from its 
prohormone proBNP, leaving a biologically-inactive fragment 
– N-terminal (NT)-proBNP. Both BNP and N-terminal pro-
B-type natriuretic peptide (NT-proBNP) are regarded as 
markers of myocardial stress, and considered to be good 
diagnostic and prognostic markers in patients with heart 
failure [8,9]. In the family of natriuretic peptides, NT-proBNP 
seems to be the best predictor of clinical outcome and the 
best marker of extracellular fluid overload. NT-proBNP has 
become an important tool for diagnosing left ventricular 
dysfunction and predicting mortality, irrespective of renal 
function in adults. However, in patients with CKD, their use 
is confounded by concomitant volume overload and reduced 
renal excretion [10]. Nevertheless, NT-proBNP is a part of the 
routine for cardiovascular risk assessment in HD patients.
Taking all these observations together, the aim of the 
presented study was to investigate renalase concentration 
and explore associations with NT-proBNP, as well as analyze 
parameters in haemodialysis patients.
MATERIALS AND METHOD
The study was conducted among residents of the municipality 
and neighbouring villages in the province of Lublin, central-
eastern Poland. 49 male subjects on haemodialysis, aged 
65.3 ± 14.2 years, median time on HD: 37.5 months, were 
included. ESRD results: diabetic nephropathy (14 patients), 
glomerulonephritis (12 patients), hypertensive nephropathy 
(9 patients), connective tissue disease (5 patients), and 
polycystic kidney disease (3 patients). In 6 patients, the 
underlying cause remained undetected. In 28 patients, 
concomitant ischemic heart disease were diagnosed, while 
21 patients were diagnosed with heart failure and qualified 
as NYHA II (6 patients) and III (15 patients) functional 
class (New York Heart Association). The study protocol 
was approved by the local Ethics Committee at the Medical 
University in Lublin. Written informed consent was obtained 
from each patient qualified to participate in the study. All 
patients underwent a clinical examination at the Department 
of Nephrology of the Medical University in Lublin.
All study subjects underwent HD 3 times a week. Each 
procedure lasted from 3.5 – 4.5 hours. Low-flux dialyzers 
were used; bicarbonate dialysate contained a calcium 
concentration of 1.5 mmol/ml. A dialyzer blood flow rate 
ranged between 230 – 400 ml/min, while the dialysate flow 
rate was 500 ml/min.
Blood samples were obtained from the venous part of the 
vascular access prior to HD. Standard phlebotomy techniques 
were used to obtain samples. The samples were collected 
in chilled tubes (EDTA) at 4 °C. Plasma was separated and 
stored at –80 °C until the assay. In the plasma, concentration 
of interleukin 6 (IL-6), high-sensitivity C-reactive protein 
(hs-CRP), NT-proBNP, albumin, and renalase were measured 
prior HD. Similarly, haematology testing was carried out 
with the blood. Moreover, several scores and parameters 
were calculated for each patient: comorbidity score (CS) 
according to the scale published by Charlson et al. [11]. HD 
adequacy was expressed by Kt/V parameter [12], normalized 
protein catabolic rate [13], body mass index (BMI), and 
mean arterial pressure (MAP). MAP was calculated on the 
basis of blood pressure measurement taken prior to HD in a 
horizontal position. The following formula was used: MAP = 
diastolic pressure + ⅓ (systolic pressure-diastolic pressure). 
The following biochemical parameters were measured 
using an enzyme-linked immunosorbent assay (ELISA): 
interleukin 6 (IL-6) and renalase (USCN Life Science, Inc.). 
NT-proBNP was measured by an electrochemiluminescence 
immunoassay using a Cobas 6000 system with e601 module 
(Roche Diagnostics, Mannheim, Germany).
Statistical analysis. All values were expressed as the mean 
and standard deviations. Distributions of the analyzed 
variables were tested using the Shapiro-Wilk test. Statistical 
relationship between the 2 variables was investigated using 
Spearman`s correlation coefficient R. In all tests, P-value 
<0.05 was considered statistically significant for differences 
or correlations. All statistical analyses were conducted using 
Statistica 10.0 software.
RESULTS
The main demographic and clinical characteristics of the 
patients included in the study are detailed in Table 1. The 
mean concentration of renalase in the entire study population 
was 126.59 ± 32.63 ng/mL. Correlations between renalase 
and different parameters are presented in Table 2. As a result 
Table 1. Demographic and biochemical characteristics of patients on 
long-term dialysis
Parameter
Mean ± Standard 
deviation
Median Range
age [years] 65.3 ± 14.2 68   45 – 92
time on HD [months] 40 ± 43.2 32.5   22 – 394
Kt/V 1.56 ± 0.23 1.62     1.01 – 1.88
BMI [kg/m2] 25.28 ± 4.27 23.9   20.01 – 32.9
nPCR [g/kg/day] 1.03 ± 0.24 1.08     0.68 – 1.49
MAP [mm/Hg] 85.27 ± 11.79 83.00   70.0 – 106.0
NT-proBNP [pg/mL] 813.74 ± 706.96 765.91   64.97 – 3189.49
IL-6 [pg/mL] 5.33 ± 2.2 5.85     1.82 – 9.57
hs-CRP [mg/l] 6.74±7.25 4.1     0.38 – 23.0
haemoglobin [g/dL] 10.36 ± 1.39 10.5     7.5 – 13.8
albumin [g/dl] 3.76 ± 0.26 3.8     3.3 – 4.3
renalase [ng/mL] 126.59 ± 32.63 127.96   30.86 – 214.07
cholesterol [mg/dl] 208.16 ± 43.85 199.0 138.0 – 288.0
triglycerides [mg/dl] 139.27 ± 44.18 132.0   51.0 – 234.0
LDL-cholesterol [mg/dl] 125.65 ± 37.21 110.0   76.0 – 204.0
HDL-cholesterol [mg/dl] 49.88 ± 12.06 50.0   25.0 – 73.0
Comorbidity score 5.61 ± 2.11 5.5     2.0 – 11.0
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of the conducted study, a significant inverse correlation 
was found between NT-proBNP and renalase plasma levels 
(R = –0.3; P = 0.03 (Fig. 1). Moreover, a positive correlation 
was noted between renalase and MAP (R = 0.43, P = 0.04), 
IL-6 (R = 0.49, P = 0.04), and albumin (R = 0.69; P = 0.008). 
In the presented study, the duration of long-term HD 
treatment did not influence the concentration of renalase 
(P = 0.46). Furthermore, no correlation could be found 
between renalase and Kt/V (P = 0.19), or any of the tested 
parameters. The circulating level of NT-proBNP was 813.64 
± 706.96 pg/mL. NT-proBNP correlations were found to be 
statistically significant (Tab. 3). NT-proBNP was inversely 
related to haemoglobin (R = – 0.38; P = 0.0001), and albumin 
(R = – 0.22; P = 0.03). NT-proBNP levels positively correlated 
with time on dialysis (R = 0.31; P = 0.002), MAP (R = 0.2; 
P = 0.04), IL-6 (R = 0.44; P = 0.001). However, the NT-proBNP 
did not correlate with Kt/V (P = 0.36) and hs-CRP (P = 0.53).
DISCUSSION
Patients with CKD represent a population not only at risk for 
progression to ESRD, but also at even greater risk for CVD. 
In addition to traditional risk factors, patients with CKD may 
have other risk factors for in increase cardiovascular risk, 
such as inflammation, oxidative stress, anaemia, metabolic 
disorders, calcium-phosphorous disorders, hypervolaemia, 
and structural and functional abnormalities of the heart, 
which may help to explain the high cardiovascular morbidity 
and mortality. Recently, it has been suggested that renalase 
is a novel, soluble monoamine oxidase that regulates cardiac 
function and blood pressure [14]. It might contribute to the 
pathophysiology of human heart failure via the increased CA 
with impaired signaling pathway, and focused to be related to 
heightened cardiovascular risk in HD patients. A recent study 
by Wu et al. [15] provides information that cardiac renalase 
deficiency may contribute to the increased susceptibility to 
myocardial injury due to ischemia and rhythm disturbances 
frequently found in CKD.
In the presented study, in HD patients it was noticed that 
the plasma concentration of renalase was more markedly 
reduced than the mean plasma renalase (386.0 ± 7.3 ng/mL) 
control group in the study presented by Zbroch and Małyszko 
[16]. Thus, it is possible that lower plasma renalase levels 
lead to the heightened sympathetic tone observed in ESRD 
patients, and that renalase administration may decrease 
the incidence of cardiovascular complication and improve 
patients survival. Renalase degrades circulating CA, causing 
a significant fall in blood pressure. In the presented study, it 
was observed that renalase expression correlated with MAP, 
suggesting that renalase plays a role in the development of 
hypertension, and thus directly or indirectly contributing to 
renal injury. The study also showed that there were elevated 
levels of cardiac biomarker NT-proBNP in the studied 
patients, with a significant inverse correlation to renalase 
levels in plasma. Focusing on these the negative correlations, 
the outcome of the current study supports the hypothesis 
renalase could play a role in heightened cardiovascular risk. 
This finding can be explained by the fact that the NT-proBNP 
are hormones released in response to volume expansion, 
increased wall stretch, and high ventricular end diastolic 
pressure, as well as high filling pressure.
NT-proBNP is released from myocytes in response to 
ventricular wall stench and wall tension. The presented study 
shows that there were elevated levels of cardiac biomarker 
NT-proBNP in the studied patients, with a significant an 
inverse correlation with renalase levels in plasma. NT-
proBNP is released from myocytes in response to ventricular 
wall stench and wall tension. The diagnostics and prognostic 
role of NT-proBNP have been well established in a variety 
of cardiac diseases. Most investigators have excluded CKD 
patients from their study because of potentially elevated levels 
of the peptide. Thus, measurement of NT-proBNP in HD 
patients may by challenging because their concentration can 
be substantially modified by the HD session. The presented 
study demonstrated that in haemodialysis patients the 
levels of NT-proBNP were increased in HD patients due to 
impaired glomerular filtration rate (GFR). These results were 
in agreement with Austin et al. [17] and Spanaus et al.[18] who 
stated that the level of NT-proBNP was significantly increased 
with more deterioration in kidney function. In addition, the 
degree of change in NT-proBNP is also dependent on the left 
Table 3. Correlations between NT-proBNP and analyzed parameters
Parameter Spearman R P
MAP 0.2 0.04
Kt/V 0.09 0.36
Haemoglobin –0.38 0.0001
Albumin –0.22 0.03
IL-6 0.44 0.0001
Time on HD 0.31 0.002
hs-CRP 0.15 0.53
Renalase –0.3 0.03
Table 2. Correlations between renalase and analyzed parameters
Parameter Spearman R P
MAP 0.43 0.04
Kt/V –0.31 0.19
Time on HD –0.18 0.04
IL-6 0.49 0.04
Albumin 0.69 0.008
hs-CRP 0.12 0.61
NT-proBNP -0.3 0.03
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Figure 1. Correlation between levels of renalase and NT-proBNP. Solid 
Line – Regresion Line; Dotted lines – 95% confidence intervals
134Annals of Agricultural and Environmental Medicine 2014, Vol 21, No 1
Marcin Dziedzic, Beata Petkowicz, Anna Bednarek-Skublewska, Janusz Solski, Agnieszka Buczaj, Piotr Choina. Relationship between renalase and N-terminal…
ventricular ejection fraction, which may reflect an increased 
volume overload of the heart as a consequence of volume 
expression due to restricted GFR.
It is interesting to note that in research by Tagore et al. [19], the 
NT-proBNP levels were significantly affected by hypertension 
and the haemoglobin level. Uraemic toxins, hypothyroidism, 
hypersplenism and ongoing infection can reduce the 
erythrocyte life span, leading to contributing to renal anaemia. 
Anaemia has been shown to be significant associated with left 
ventricular hypertrophy in dialysis patients. Therefore, anaemia 
can be an important novel risk factor in CKD patients. The 
present findings are in agreement with Saha [20], Afshar [21] 
and Ijoma et al. [22], who stated a high prevalence of anaemia in 
CKD patients. In agreement with data from medical literature, 
that albuminuria in CKD may represent diffuse endothelial 
damage, and hence is considered as novel cardiac risk factor, 
it can therefore be considered as cardiac biomarker in CKD 
patients [23, 24]. In the presented study, the majority of patients 
had hypoalbumenaemia. Hypoalbuminaemia may be due to 
albuminuria and/or nutritional deficiency which may lead to 
malnutrition, infection and atherosclerosis, and predispose 
to cardiovascular events in CKD. Moreover, inflammation 
in ESRD patients is a multi-factorial problem. Both dialysis-
related and dialysis-independent factors may promote 
inflammation by stimulating the synthesis and/or release of 
several pro-inflammatory cytokines, such as CRP, IL-1, IL-6, 
and Tumour Necrosis Factor (TNF-α); [25]. Circulating levels 
of NT-proBNP were directly and significantly related to IL-6, 
indicating that inflammation and endothelial dysfunction are 
parallel processes in ESRD.
CONCLUSIONS
In conclusion, the results of the presented study demonstrate an 
inverse correlation between NT-proBNP and renalase plasma 
levels in haemodialysis patients. Indeed, elevated renalase 
levels in HD patients may be due to impaired kidney function, 
and may have an impact on the development of hypertension 
and cardiovascular complications. It is hypothesised that 
abnormalities in the renalase pathway and high concentration 
of CA with NT-proBNP in blood contribute to the heightened 
cardiovascular risk observed in HD patients. Therefore, it can 
be stated that apart from having an action on physiological 
blood pressure regulation, increasing evidence suggests a 
role for renalase in the development of pathophysiological 
states of the cardiovascular system in renal failure. It is 
worth pointing out that renalase may provide the missing 
link between hypertension and cardiovascular disease in 
haemodialysis patients. Further studies are needed to prove 
or disprove the possible role of renalase in the pathogenesis 
of hypertension in haemodialysis patients.
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